In July 2010, President Obama signed the Dodd-Frank Wall Street Reform and Consumer Protection Act that greatly expanded whistleblower bounties in connection with violations of federal securities laws, including the Foreign Corrupt Practices Act. Discussing business protection strategies and best practices in dealing with whistleblowers, Whistleblowers will appeal to board members, executives, corporate compliance personnel, attorneys for whistleblowers and defense attorneys, as well as potential employee whistleblowers.
- Case studies of GlaxoSmithKline, Pfizer and other high profile whistleblower incidences
- Examines new Dodd-Frank incentives to whistleblowers
- Recommends best practices for corporations in light of new whistleblowing incentives
- Explores other federal and state statutory incentives to whistleblowing
Timely and comprehensive, Whistleblowers emphasizes the disincentives to whistleblowing, reviewing the academic studies of whistleblowers with the idea of developing best practices in working with whistleblowers.
Keywords: Risk, Contingency & Crisis Management, Frederick Lipman, whistleblowers, dodd-frank act, FCPA act, foreign corrupt practices act, whistleblower best practices, whistleblower incentives, SEC whistleblower rules, Pfizer, Cheryl Eckard, GlaxoSmithKline, compliance management for public, private, or non-profit organizations, Michael silverman, Cynthia cooper, worldcom, enron,